10-K: Rafael Holdings Reports FY25 Results, Cyclo Merger Impact

Rafael Holdings reported a reduced net loss for fiscal year 2025, driven by the Cyclo merger and R&D efforts, while advancing its lead drug candidate Trappsol Cyclo for NPC1.

Summary

• Reported a consolidated net loss of $30.6 million for the fiscal year ended July 31, 2025, an improvement from a $65.0 million loss in the prior year.
• Total revenue increased to $917 thousand for FY2025, up from $637 thousand in FY2024, primarily due to the inclusion of product revenue from Cyclo post-merger.
• Research and development expenses increased to $12.8 million in FY2025 from $4.2 million in FY2024, largely due to the consolidation of Cyclo's R&D expenses ($8.4 million).
• The Healthcare segment's loss from operations was $25.3 million in FY2025, a significant reduction from $102.0 million in FY2024, mainly due to the absence of a large in-process research and development expense.
• The Infusion Technology segment recorded a $3.1 million goodwill impairment charge during FY2025 due to reductions in operations, including layoffs.
• Cash and cash equivalents increased substantially to $52.8 million as of July 31, 2025, from $2.7 million in 2024, bolstered by a $25.0 million rights offering.
• The merger with Cyclo Therapeutics was consummated on March 25, 2025, making Cyclo a wholly-owned subsidiary.
• Rafael Medical Devices received FDA 510(k) clearance for its VECTR System on December 11, 2024, for minimally invasive ligament or fascia release surgeries.
• Day Three Labs Manufacturing sold assets and licensed certain Unlokt technology applications for a $500,000 convertible note and potential future milestone payments on March 14, 2025.
• A material weakness was identified in Cyclo's internal controls over financial reporting related to accruals and expense recognition post-merger.

Sentiment

Score: 4

Explanation: While the net loss decreased and the Cyclo merger advanced the lead candidate, significant setbacks in other portfolio companies (Cornerstone, LipoMedix, Barer curtailment) and the goodwill impairment in Infusion Technology, coupled with internal control weaknesses, indicate ongoing challenges and uncertainty. The positive cash position from the rights offering is a temporary boost, but long-term profitability remains elusive.

Positives

• Consolidated net loss significantly reduced to $30.6 million in FY2025 from $65.0 million in FY2024.
• Total revenue increased by 44% to $917 thousand in FY2025.
• The merger with Cyclo Therapeutics was successfully completed, integrating Trappsol Cyclo as a core asset.
• The independent Data Monitoring Committee (DMC) recommended continuing the Trappsol Cyclo Phase 3 study for the full 96 weeks after reviewing the 48-week interim analysis, indicating the drug was well-tolerated.
• Rafael Medical Devices received FDA 510(k) clearance for its VECTR System, enabling commercialization for minimally invasive orthopedic surgeries.
• The company's cash and cash equivalents balance increased to $52.8 million, providing sufficient liquidity for at least the next 12 months.
• A $25.0 million rights offering was successfully completed, with significant participation from the controlling stockholder.
• Trappsol Cyclo holds Orphan Drug, Fast Track, and Rare Pediatric Disease Designations, offering potential market exclusivity upon approval.

Negatives

• Despite improvement, the company reported a substantial net loss of $30.6 million for the fiscal year.
• The Infusion Technology segment incurred a $3.1 million goodwill impairment charge due to operational reductions, including layoffs.
• Cornerstone Pharmaceuticals' lead candidate, Devimistat, received negative Phase 3 study results in October 2021, leading to the impairment of related investments.
• LipoMedix's Promitil Phase IIa clinical trial did not meet its efficacy endpoints.
• Barer Institute's early-stage development efforts have been substantially curtailed.
• Customer concentration risk exists, with one major customer accounting for 25% of total revenues in FY2025.
• Interest income decreased due to the reallocation of assets and lower interest rates.
• A material weakness was identified in Cyclo's internal controls over financial reporting post-merger, specifically concerning accruals and expense recognition.
• Operations are exposed to political, economic, and military conditions in Israel, including ongoing regional instability.

Risks

• Limited resources and potential difficulty in raising additional capital for operations and commercialization of Trappsol Cyclo.
• The lengthy, expensive, and uncertain nature of preclinical and clinical drug development, with potential for delays or failure to advance programs.
• Uncertainty regarding the Rare Pediatric Disease Priority Review Voucher Program, which may no longer be in effect or its value may not be realized.
• Dependence on third parties for manufacturing, clinical trials, and other critical functions, which may not provide expected benefits or maintain quality standards.
• Preclinical and early clinical trial results may not be predictive of future success in later-stage trials.
• Substantial competition from other pharmaceutical, biotechnology, and medical device companies with greater resources.
• Rafael Medical Devices' device candidates may cause significant adverse events or undesirable side effects, potentially preventing regulatory approval or market acceptance.
• Significant reliance on information technology, with risks of failure, inadequacy, interruption, or cybersecurity incidents.
• Inability to consummate future investments, business combinations, or other strategic transactions.
• Control by the principal stockholder (Howard S. Jonas) limits the ability of other stockholders to affect company management.
• Inability to adequately maintain or protect proprietary technology and product/device candidates, or insufficient patent protection.
• Potential for product liability lawsuits, which could result in substantial liabilities and limit commercialization.
• Failure to comply with environmental, health, and safety laws and regulations, leading to fines or penalties.
• Adverse effects from healthcare reform initiatives, unfavorable pricing regulations, or inadequate third-party coverage and reimbursement practices.
• Negative impacts from currency exchange rate fluctuations and tariffs on imported/exported products.
• Challenges in successfully integrating Cyclo's team and operations post-merger.
• Risks associated with future acquisitions or strategic collaborations, including increased capital requirements, dilution, and assumption of liabilities.
• Volatility in the trading price of Class B common stock.
• Potential for securities litigation.
• Adverse effects on operations and financial condition due to political, economic, and military conditions in Israel.
• Inadequate insurance coverage for various business risks, including product liability and hazardous waste.

Future Outlook

The primary focus remains on the continued development of Trappsol Cyclo through its ongoing pivotal Phase 3 clinical trial, potential regulatory approval, and commercialization. The company also seeks to expand its investment portfolio through opportunistic and strategic investments addressing high unmet medical needs, while continuously evaluating other holdings to focus resources on core assets. Future product development for Rafael Medical Devices depends on the success of the VECTR System and identifying attractive market opportunities. The company expects to operate Barer primarily as an entity holding interest in two cancer-focused opportunities.

Management Comments

• We continuously evaluate our other holdings to ensure the focus of our resources are on core assets and specifically the continued development of Trappsol Cyclo.
• The Company is currently reviewing Cornerstones current efforts, prospects and available resources to determine its optimal operational direction.
• Rafael Medical Devices' development of future products will depend upon the success of the VECTR System and our Company's ability to identify attractive opportunities in the marketplace.
• We do not anticipate paying dividends on our common stock until we achieve sustainable profitability (after satisfying all of our operational needs) and retain certain minimum cash reserves.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies and intense competition. Rafael Holdings operates in the orphan drug space for NPC1, facing competition from established players like Johnson & Johnson and Zevra Therapeutics. In cancer metabolism, Cornerstone faces competition from major pharmaceutical companies and biotechnology firms. The medical device sector is also highly competitive, with a focus on minimally invasive surgeries. The regulatory environment is increasingly stringent, with evolving policies on drug pricing and data transparency, such as the FDA's recent policy of publishing complete response letters and the Inflation Reduction Act's impact on Medicare drug costs.

Comparison to Industry Standards

• Trappsol Cyclo has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations, which are regulatory incentives for therapies addressing unmet medical needs, potentially offering market exclusivity (7 years in US, 10-12 years in EU) if approved.
• Two competitors for NPC1 treatment received FDA approval in September 2024 and became commercially available in 2025, indicating a competitive landscape for Trappsol Cyclo.
• Cornerstone's Devimistat had negative Phase 3 results, a common setback in the biopharmaceutical industry where many compounds fail in late-stage trials despite early promise.
• The FDA's 510(k) clearance for Rafael Medical Devices' VECTR System is a standard pathway for Class II medical devices, indicating substantial equivalence to existing legally marketed devices.
• The company's reliance on third-party manufacturers and CROs is a common industry practice, but also introduces risks related to quality control, compliance, and supply chain disruptions.

Management Changes

Corporate Governance

Legal Proceedings

• The Company may from time to time be subject to legal proceedings that arise in the ordinary course of business. No expectation for any of these to have a material adverse effect on the Company's results of operations, cash flows, or financial condition.

Related Party Transactions

• IDT Corporation, a related party, billed the Company approximately $275 thousand for services in FY2025 and owed $93 thousand for office rent and parking as of July 31, 2025.
• Related party rental income represented approximately 12% of the Company's total revenue for FY2025.
• Howard S. Jonas, the controlling stockholder, purchased 16,386,020 shares of Class B common stock for approximately $21.0 million in a private placement as part of the Rights Offering.
• Joshua Fine, the Chief Operating Officer, is the son of N. Scott Fine, who serves as an ex-officio director and Vice Chairman of the Company's Board of Directors.
• The Company invested $500,000 in NINA Medical Ltd., a related party through Howard S. Jonas's indirect investment.
• Sam Beyda, Howard Jonas's son-in-law, received wages of $142 thousand and a bonus of $33 thousand in FY2025 as CEO and Director of Day Three.

Stakeholder Impact

• Shareholders: Experienced dilution from the rights offering, face potential stock price volatility, and have limited influence due to the controlling stockholder. Potential for future appreciation is tied to the success of Trappsol Cyclo.
• Employees: Some employees in the Infusion Technology segment were affected by layoffs. Changes in executive roles and stock-based compensation plans are noted.
• Customers: Patients with NPC1 may benefit from the continued development of Trappsol Cyclo. Orthopedic surgeons gain a new tool with the FDA-cleared VECTR System. Third-party manufacturers can utilize Day Three Labs' Unlokt technology.
• Creditors: Cornerstone has a forbearance agreement with a major creditor, with future payments contingent on FDA approval and capital raises, indicating some risk for creditors.

Next Steps

• Complete the ongoing pivotal Phase 3 clinical trial for Trappsol Cyclo.
• Potentially file for regulatory approval and commercialize Trappsol Cyclo if approved.
• Expand the investment portfolio through opportunistic and strategic investments addressing high unmet medical needs.
• Continuously evaluate other holdings to focus resources on core assets, specifically Trappsol Cyclo.
• Rafael Medical Devices to initiate sales efforts in the United States and build a network of distributors for the VECTR System.
• Rafael Medical Devices to initiate design of its second product, a retrograde release system.
• LipoMedix to explore strategic options for Promitil, including licensing and collaborations.
• Remediate the material weakness identified in Cyclo's internal controls over financial reporting.
• Evaluate the potential impact of new FASB accounting standards (ASU 2023-09, ASU 2024-03).
• The Annual Meeting of Stockholders is to be held on January 8, 2026.

Key Dates

Recommendation

Rafael Holdings presents a mixed bag of developments. The significant reduction in net loss and the advancement of Trappsol Cyclo into Phase 3 with positive interim data are encouraging. The FDA clearance for the VECTR System also provides a new commercial avenue. However, the negative clinical trial results for other portfolio companies (Cornerstone, LipoMedix), the curtailment of Barer's operations, and the goodwill impairment in the Infusion Technology segment highlight ongoing challenges and resource allocation issues. The identified material weakness in Cyclo's internal controls adds a layer of operational risk. While the recent capital raise strengthens the balance sheet, the company's long-term profitability is still uncertain and heavily reliant on the success of Trappsol Cyclo. Given the high-risk, high-reward nature of biotech development and the mixed performance across its diverse portfolio, a 'hold' recommendation is appropriate, awaiting further clarity on Trappsol Cyclo's path to commercialization and the effective remediation of internal control issues.

Keywords

Biotechnology, Pharmaceuticals, Medical Devices, Niemann-Pick Disease Type C1, NPC1, Trappsol Cyclo, Clinical Trials, FDA Clearance, VECTR System, Orphan Drug, Rare Pediatric Disease, Cyclodextrin, Cancer Metabolism, Corporate Governance, Financial Results, Risk Factors, Capital Raise, Merger, Day Three Labs, LipoMedix, Cornerstone Pharmaceuticals, SEC Filing, 10-K